Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk
View original at nasdaq.comWhy This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk Key Points Viking Therapeutics has a weight-loss program that looks to be competitive with medicines already on the market…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Viking Therapeutics could have a harder time competing against Eli Lilly's and Novo Nordisk's late-stage pipeline candidates than against their currently marketed products
60% confidenceThe market for anti-obesity drugs is at risk of calcifying into a dominant duopoly between Eli Lilly and Novo Nordisk
60% confidenceSeizing even 1% of the projected $100 billion anti-obesity market would lift Viking Therapeutics' valuation well above its current $3.5 billion market cap
60% confidenceRetatrutide phase 3 results showed 45% of subjects lost at least 30% of their body weight after 80 weeks
60% confidenceViking Therapeutics was not among The Motley Fool Stock Advisor's 10 best stocks to buy now
60% confidenceThe market for weight loss medicines could reach $100 billion before the end of the decade, according to some analysts
60% confidenceVK2735 oral formulation Phase 3 trial is expected to begin around the end of 2026
60% confidenceEli Lilly and Novo Nordisk together hold nearly the entire U.S. market for branded obesity and diabetes treatments
60% confidenceThe odds of VK2735 being approved and becoming a decisive win for Viking Therapeutics are slim; it is still an underdog in the GLP-1 market
60% confidenceVK2735's weight loss performance in its 13-week phase 2 study looks competitive with currently approved market leaders
60% confidenceWeight loss on GLP-1 drugs tends to slow the longer people stay on them
60% confidenceCross-trial comparisons between VK2735 and approved GLP-1 drugs are suggestive rather than direct due to different patients, doses, and follow-up lengths
60% confidenceIn VK2735's injectable phase 2 trial, the pace of weight loss didn't appear to be tapering at the end of the study period, suggesting patients could lose more weight by staying on treatment longer
60% confidenceVK2735 injectable phase 3 top-line data will not arrive before 2027 given the study runs well over a year
60% confidenceRetatrutide added glucagon as a third receptor target on top of the GLP-1/GIP pairing, making it a triple agonist
60% confidence